<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094755</url>
  </required_header>
  <id_info>
    <org_study_id>D5130L00047/ISSBRIL0152</org_study_id>
    <nct_id>NCT02094755</nct_id>
  </id_info>
  <brief_title>Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)</brief_title>
  <official_title>Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb
      loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a
      major cause of death and disability (secondary to myocardial infarction, stroke and
      amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years
      respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin
      and clopidogrel (previously referred to as &quot;resistance&quot;) is associated with an increased risk
      of recurrent cardiovascular events after percutaneous coronary interventions and acute
      coronary syndromes. The prevalence and significance of High on-treatment Platelet Reactivity
      (HPR) in patients with critical limb ischemia treated with aspirin and/or clopidogrel is not
      known.

      The investigators project aims to investigate the prevalence of HPR (to aspirin and
      clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at
      University of Southern California (USC) affiliated hospitals (Los Angeles County Hospital and
      Keck Hospital of University of Southern California).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective clinical study will investigate the prevalence of high on- treatment
      platelet reactivity (HPR) in one hundred patients with critical limb ischemia (CLI), at the
      Keck Hospital of USC and Los Angeles County Medical Center (LAC+USC). Platelet inhibition to
      aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet
      inhibition will be evaluated with two different tests: the vasodilator-stimulated
      phosphoprotein (VASP) and the VerifyNow® purigenic receptor P2Y12 (VN-P2Y12) assays. All
      platelet function analyses will be performed once after a minimum of one week of
      uninterrupted dual antiplatelet therapy with aspirin and clopidogrel. High on-treatment
      Platelet Reactivity on aspirin treatment (HPRA) group will be defined as aspirin reaction
      units (ARU) ≥550 by the VerifyNow® ASA assay. High on-treatment Platelet Reactivity on
      clopidogrel (HPRC) group will be defined as P2Y12 reaction units (PRU) ≥208 by the VerifyNow®
      assay and Vasodilator-stimulated phosphoprotein-platelet reactivity index (VASP-PRI) ≥50% by
      the vasodilator-stimulated phosphoprotein (VASP) assay. All other patients will be assigned
      to the adequate platelet reactivity on therapy (APR) group. Prevalence of high on-treatment
      platelet reactivity will then be calculated for aspirin and/or clopidogrel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2013</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</measure>
    <time_frame>Single measurment after a minimum of one week of uninterrupted dual antiplatelet therapy with aspirin and clopidogrel</time_frame>
    <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Single cohort</arm_group_label>
    <description>Single cohort will receive Blood draw only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw only</intervention_name>
    <description>Blood draw only</description>
    <arm_group_label>Single cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Draw
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will include one-hundred patients with a diagnosis of CLI. We will
        only include in the study CLI patients who as part of their standard of care medical
        treatment are receiving dual antiplatelet therapy with aspirin 81 mg and clopidogrel 75 mg
        daily for at least one week.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  EXPERIMENTAL GROUP: Patients with a diagnosis of critical limb ischemia (CLI) and
             uninterrupted treatment with aspirin and/or clopidogrel for at least one week before
             testing.

          -  CONTROL GROUP: 10 normal volunteers without any known co-morbidities

        Exclusion Criteria:

          -  Chronic use of nonsteroidal anti-inflammatory drugs, thrombocytopenia (platelet count
             &lt;100 × 103/μl), use of an oral anticoagulant (warfarin), glycoprotein (GP) IIb/IIIa
             inhibitors, or fibrinolytic drugs within 30 days before testing. Any documented
             history of hypercoaguable states or history of medication non-compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Clavijo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Leonardo Clavijo</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine Director of Vascular Medicine &amp; Peripheral Interventions</investigator_title>
  </responsible_party>
  <keyword>ASA-PLAVIX Reactivity in CLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</title>
        <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
        <time_frame>Single measurment after a minimum of one week of uninterrupted dual antiplatelet therapy with aspirin and clopidogrel</time_frame>
        <population>High on-treatment platelet reactivity on clopidigrel (HPRC) was defined as VerifyNow®P2Y12 reactive units (PRU) &gt;208 and VASP-platelet reactivity index (VASP-PRI) &gt;50%.
Thromboxane A2 (TXA2) inhibition was measured with the VerifyNow®aspirin test and High on-treatment reactivity on aspirin (HPRA) was defined as aspirin reaction units (ARU) &gt;550.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Cohort</title>
            <description>Patients were included who had a diagnosis of CLI and who received uninterrupted treatment with ASA and/or clopidogrel for ≥1 week prior to platelet inhibition testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</title>
          <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
          <population>High on-treatment platelet reactivity on clopidigrel (HPRC) was defined as VerifyNow®P2Y12 reactive units (PRU) &gt;208 and VASP-platelet reactivity index (VASP-PRI) &gt;50%.
Thromboxane A2 (TXA2) inhibition was measured with the VerifyNow®aspirin test and High on-treatment reactivity on aspirin (HPRA) was defined as aspirin reaction units (ARU) &gt;550.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HPR on Clopidogrel</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HPR on Aspirin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HPR on Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>API on Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Critical limb ischemia patients with clinical indication of aspirin and clopidogrel dual antiplatelet therapy with for at least 1 week as standard of care, were monitored for adverse events for the length of study participation which was 1 day from study enrollment to the last study intervention.</time_frame>
      <desc>In adherence to the clinical trials.gov adverse event and serious adverse event definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leonardo Clavijo</name_or_title>
      <organization>University of Southern California</organization>
      <phone>3234426130</phone>
      <email>lclavijo@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

